Targeting an infectious disease with a high mortality rate and growing incidence driven by climate change.
By Elric Langton | 21 September 2022
I have a financial interest in Poolbeg Pharma & Open Orphan.
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical-stage infectious disease pharmaceutical company with a unique capital light clinical model, announceβ¦